Physician profile
Brett L Ferrell
NPI 1356646434
$11,367.46
in general payments reported to CMS, 2019-2025
61 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,345 · 2020: $1,563 · 2021: $1,649 · 2022: $1,895 · 2023: $1,418 · 2024: $1,399 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,914.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,823.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $832.86 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $829.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $744.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $635.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.29 | 2019-2025 | Jardiance, Jascayd |
| Abbvie INC. | $479.67 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $437.33 | 2019-2024 | |
| Esperion Therapeutics, INC. | $375.39 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $339.94 | 2019-2025 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $275.86 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.01 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $256.54 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $248.28 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $235.97 | 2021-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.